Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications
Abstract Liquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the current landscape of cancer diagnostics and treatment. However, the existing methods for cfDNA-based liquid biopsies for cancer have certain limitations, such as fragment interruption and GC bias, w...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-024-02178-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846148065062289408 |
|---|---|
| author | Hua-Qi Si Peng Wang Fei Long Wei Zhong Yuan-Dong Meng Yuan Rong Xiang-Yu Meng Fu-Bing Wang |
| author_facet | Hua-Qi Si Peng Wang Fei Long Wei Zhong Yuan-Dong Meng Yuan Rong Xiang-Yu Meng Fu-Bing Wang |
| author_sort | Hua-Qi Si |
| collection | DOAJ |
| description | Abstract Liquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the current landscape of cancer diagnostics and treatment. However, the existing methods for cfDNA-based liquid biopsies for cancer have certain limitations, such as fragment interruption and GC bias, which are likely to be resolved by the emerging Oxford Nanopore Technologies (ONT), characterized by long read-length, fast read-times, high throughput, and polymerase chain reaction-free. In this review, we summarized the current literatures regarding the feasibility and applications of cfDNA-based liquid biopsies using ONT for cancer management, a possible game-changer that we believe is promising in detecting multimodal biomarkers and can be applied in a wide range of oncology utilities including early screening, diagnosis, and treatment monitoring. Graphical abstract |
| format | Article |
| id | doaj-art-d3eec59b26f3478d99d35ef08b165c45 |
| institution | Kabale University |
| issn | 1476-4598 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj-art-d3eec59b26f3478d99d35ef08b165c452024-12-01T12:12:56ZengBMCMolecular Cancer1476-45982024-11-0123111510.1186/s12943-024-02178-6Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applicationsHua-Qi Si0Peng Wang1Fei Long2Wei Zhong3Yuan-Dong Meng4Yuan Rong5Xiang-Yu Meng6Fu-Bing Wang7Department of Laboratory Medicine, Zhongnan Hospital of Wuhan UniversityDepartment of General Surgery, Renmin Hospital of Wuhan UniversityDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan UniversityDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan UniversityHubei Provincial Clinical Medical Research Center for Nephropathy, Hubei Minzu UniversityCenter for Single-Cell Omics and Tumor Liquid Biopsy, Zhongnan Hospital of Wuhan UniversityHubei Provincial Clinical Medical Research Center for Nephropathy, Hubei Minzu UniversityDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan UniversityAbstract Liquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the current landscape of cancer diagnostics and treatment. However, the existing methods for cfDNA-based liquid biopsies for cancer have certain limitations, such as fragment interruption and GC bias, which are likely to be resolved by the emerging Oxford Nanopore Technologies (ONT), characterized by long read-length, fast read-times, high throughput, and polymerase chain reaction-free. In this review, we summarized the current literatures regarding the feasibility and applications of cfDNA-based liquid biopsies using ONT for cancer management, a possible game-changer that we believe is promising in detecting multimodal biomarkers and can be applied in a wide range of oncology utilities including early screening, diagnosis, and treatment monitoring. Graphical abstracthttps://doi.org/10.1186/s12943-024-02178-6Oxford Nanopore TechnologiesCell-free DNAOncologyLiquid biopsiesDiagnosisPersonalized medicine |
| spellingShingle | Hua-Qi Si Peng Wang Fei Long Wei Zhong Yuan-Dong Meng Yuan Rong Xiang-Yu Meng Fu-Bing Wang Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications Molecular Cancer Oxford Nanopore Technologies Cell-free DNA Oncology Liquid biopsies Diagnosis Personalized medicine |
| title | Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications |
| title_full | Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications |
| title_fullStr | Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications |
| title_full_unstemmed | Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications |
| title_short | Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications |
| title_sort | cancer liquid biopsies by oxford nanopore technologies sequencing of cell free dna from basic research to clinical applications |
| topic | Oxford Nanopore Technologies Cell-free DNA Oncology Liquid biopsies Diagnosis Personalized medicine |
| url | https://doi.org/10.1186/s12943-024-02178-6 |
| work_keys_str_mv | AT huaqisi cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications AT pengwang cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications AT feilong cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications AT weizhong cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications AT yuandongmeng cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications AT yuanrong cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications AT xiangyumeng cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications AT fubingwang cancerliquidbiopsiesbyoxfordnanoporetechnologiessequencingofcellfreednafrombasicresearchtoclinicalapplications |